Novavax Inc. Stock Underperforms Wednesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Novavax Inc. (NVAX) shares fell 2.04% to $7.91 on Wednesday, underperforming competitors like Johnson & Johnson and Merck during a generally weak market session. The stock closed 33.92% below its 52-week high of $11.97. Trading volume was notably lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Novavax Inc. (NVAX) slipped 2.04% to $7.91 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.57% to 25,690.90 and Dow Jones Industrial Average falling 0.01% to 52,218.58.
Novavax Inc. closed 33.92% short of its 52-week high of $11.97, which the company reached on February 26th.
The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) rose 2.00% to $255.63, Pfizer Inc. (PFE) fell 0.48% to $24.82, and Merck & Co. Inc. (MRK) rose 0.96% to $127.47.
Trading volume (2.6 M) remained 2.2 million below its 50-day average volume of 4.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 22, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-22-26 1727ET